The proposed approach does not provide transparency as to which patents are relevant to particular therapeutic products.

The High Court affirmed the Full Federal Court's decision that AstraZeneca's low dose rosuvastatin patent was obvious.

WADA has requested that CAS issue a finding that the players have committed an ADRV and impose an "appropriate sanction".

This is the first major trial in Australia of alleged negligence causing contamination of organic land with GM material.

Over the past 12 months, approximately 24 countries have either legalised or commenced the legalisation process for medicinal cannabis.

Multinational food manufacturers and operators should be prudent and careful when managing their businesses in China.

A patient who regularly uses medicinal cannabis to treat their ailments recently remarked about the delay in supply.

Future action for non-compliance with the ACL in the marketing of therapeutic goods may result in much higher penalties.

Government regulations ban offering "alcohol, tobacco or registered medicines" as incentives for COVID-19 vaccinations.

Operation Ironside led to 224 arrests in Australia and other countries have been able to break up major crime syndicates.

Possessing some pharmaceutical medicines without a valid prescription can amount to a criminal offence.

US and Australian patent laws both include exceptions to patent infringement for regulatory and experimental activities.

The article details five advantages of allowing clinical trials in Australia and the requirement to have a local sponsor.

New regulations on cosmetic injections like Botox follow hospitalisations from botched treatments.

A new legislative framework for regulated substances is about to overhaul the status quo in Queensland.

The implementation of the US rules is of interest as it could indicate the future direction for disclosure in Australia.

Australia's two largest grocery retailers and the AFGC have finally reached agreement on a new industry code of conduct.

The regulatory processes available for follow-on biologicals differ between jurisdictions; Several issues need urgent clarification for many pharmaceutical manufacturers.

The issue of reforming class actions for pharmaceutical claims is highlighted in this article on the Vioxx litigation.

Australia has established a national scheme for the development of cannabis for medicinal and scientific research purposes.